EN DE
Watch Akeso, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Akeso, Inc. (AKESF) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Akeso, Inc. stock $7.47, price $11.45, that is 34.8% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in China

AI Akeso, Inc. logo Thin data Nov 10, 2026

Akeso, Inc.

AKESF · US
Expensive, weak quality

Our calculation puts a fair price 35% below what the stock costs today.

Low debt
Revenue last quarter +50% vs. a year ago.
Mixed Growth (revenue 3y +53.9 %/yr in CNY)
Neutral coverage
Fair value $7.47 · Overvalued
Quality 30/100
Loss-making · -36.4% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 12/100
Thin data
Estimate

Risks from the AI analysis

🚩Share placement dilution under China pricing pressure🚩Rivals like BioNTech BNT327 and AZ Volrustomig🚩BIOSECURE Act threatens Summit licence
Watch Akeso, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$22.92 $4.30 Fair Value $7.47 May 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

42‑month range $4.30 – $22.92 · fair‑value band $5.60 – $9.34 · the $11.45 price screens above the $7.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Akeso in your weekly email

Every Wednesday you see whether Akeso is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.

Show moreShow less

The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.

It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis.

Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

Stock analysis

Akeso, Inc. (AKESF) currently trades at $11.45, while our estimate is $7.47, 35% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.60 (bear) to $9.34 (bull), the price of $11.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Akeso, Inc. reported revenue of 3.1B CNY in FY2025 versus 226M CNY in FY2021, a compound +91.8%/yr. Reported net income was −1.1B CNY in FY2025.

Key figures

Market cap $10.5B Large · P/S ratio 3.42 · EPS (TTM) $−0.1800 · Net margin −36.4% · Return on equity −14.5% · Return on assets (EBIT) −6.8% (5-year average) · Operating margin −30.7% · Revenue (TTM) 3.1B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −35%, AKESF screens richer than that median.

Fair Value

Bear $5.60 Fair Value $7.47 Bull $9.34
Price $11.45 · Downside -34.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 53
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+43.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−561.3% (2021) → −27.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AKESF screens overvalued: fair value 35% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Note from the team Nov 12, 2026
AI conclusion: Akeso shows a narrow moat via rising revenue from innovative drugs as its main strength, while slowly narrowing net losses and dilution form its key weakness.
Main risk: Named competitors such as BioNTech/BMS BNT327, AstraZeneca Volrustomig and Pfizer/3SBio candidates could capture market share in the PD-1 x VEGF space or force price cuts on ivonescimab and cadonilimab, squeezing margins.
Bull case: Akeso could leverage its Tetrabody platform and AI-driven discovery to develop differentiated next-generation bispecifics or ADCs that outpace rivals and secure new global partnerships despite geopolitical hurdles.
Bear case: Intensifying competition together with regulatory barriers for the Summit partnership could prevent Akeso from achieving sustainable profitability as pricing pressure in China persists and global revenues remain limited.
Akeso posts rising revenue from its innovative drugs alongside fresh trial successes for ivonescimab, yet the company still reports net losses that narrow only slowly. A share placement earlier this autumn introduced dilution just as questions grew over how fast margins can improve under China pricing pressure and competition. Will the pipeline momentum close the profitability gap faster than further capital needs emerge, or will those execution realities continue to dominate?
Join the discussion →

Compare Akeso, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −34.8% · Below median
Profitability
Return on assets −7.0% · Above median
Net margin (12 months) −36.4% · Below median
Operating margin (12 months) −30.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 49.6% · Top 25%
Balance sheet
Debt / equity 0.44× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.77× · Priciest 25%
P/S (12 months) 23.02× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)78 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs AKESF
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs AKESF
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs AKESF
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs AKESF
argenx SE ARGX $977.58 $908.40 −7% vs AKESF
CSL Limited CSL A$204.54 A$181.40 −11% vs AKESF
Moderna, Inc MRNA $248.69 $158.70 −36% vs AKESF
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs AKESF
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs AKESF
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs AKESF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Akeso, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Akeso, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/AKESF

Frequently asked questions

Is Akeso, Inc. (AKESF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $7.47 versus a price of $11.45, about 35% lower (overvalued).
What is the fair value of AKESF?
Our estimate for Akeso, Inc. is $7.47 (as of Nov 10, 2026), built from audited fundamentals. The current price: $11.45.
What is the quality score of AKESF?
Akeso, Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Akeso, Inc. (AKESF)?
Our calculated price target is the estimate of $7.47 (as of Nov 10, 2026). Cautious scenario $5.60, optimistic scenario $9.34. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Akeso, Inc. stock forecast for 2026?
Our estimate puts fair value at $7.47, about 35% lower versus a price of $11.45 (overvalued). Cautious scenario $5.60, optimistic scenario $9.34. The calculation is refreshed regularly with new filings.
What is the revenue of Akeso, Inc. (AKESF)?
Akeso, Inc. reported trailing-twelve-month revenue of about 3.1B CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Akeso, Inc. (AKESF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Akeso, Inc. it is $7.47 per share (as of Nov 10, 2026), against a price of $11.45.
Is Akeso, Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AKESF trades above its calculated fair value: price $11.45, fair value $7.47, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AKESF?
No. The price is what the market pays today ($11.45); the fair value is what the company's own numbers justify ($7.47). For Akeso, Inc. the two are $3.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Akeso, Inc. worth?
The market values Akeso, Inc. at about $10.5B (market capitalisation, as of Nov 10, 2026). Per share that is $11.45; our models calculate a fair value of $7.47 per share.
What do the bullish and bearish scenarios say about AKESF?
Our models span a range for Akeso, Inc.: cautious scenario $5.60, base $7.47, optimistic $9.34 per share (as of Nov 10, 2026, price $11.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Akeso, Inc. (AKESF)?
Balance-sheet figures for Akeso, Inc. (as of Nov 10, 2026): return on equity −14.5%, debt of 0.44 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is AKESF from its 52-week high?
Akeso, Inc. trades at $11.45, about 41% below its 52-week high of $19.30 and 15% above the low of $10.00 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $7.47 is for.
Which stocks are comparable to Akeso, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Akeso, Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $11.45, calculated fair value $7.47 (−35%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Akeso, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Akeso, Inc. (AKESF)?
The closing price on Nov 10, 2026 was $11.45. Our estimate is $7.47, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Akeso, Inc. right now?
The price sits above even our optimistic bull case ($9.34). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Akeso, Inc.

How large is the market capitalisation of Akeso, Inc. (AKESF)?
The market capitalisation of Akeso, Inc. is $10.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Akeso, Inc. (AKESF)?
The price-to-sales ratio of Akeso, Inc. is 3.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Akeso, Inc. (AKESF)?
Earnings per share at Akeso, Inc. are $−0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Akeso, Inc. (AKESF)?
The net margin of Akeso, Inc. is −36.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Akeso, Inc. (AKESF)?
The return on equity (ROE) of Akeso, Inc. is −14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Akeso, Inc. (AKESF)?
On an EBIT basis the return on assets of Akeso, Inc. is −6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Akeso, Inc. (AKESF)?
The operating margin of Akeso, Inc. is −30.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Akeso, Inc. (AKESF)?
Revenue at Akeso, Inc. is growing +49.6% versus a year earlier (3y avg +53.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Akeso, Inc. (AKESF) generate?
The free cash flow of Akeso, Inc. is −1.7B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Akeso, Inc. in the live analysis

One click puts Akeso, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.